Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 13Completed 12Withdrawn 3Unknown 3Terminated 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2CNS 2

Conditions

Neuroendocrine Tumors 2von Hippel-Lindau Disease 1Paraganglioma 1Neuroblastoma 1Multiple Endocrine Neoplasia Type 1 1Meningioma 1Carcinoid Tumor 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × gallium Ga 68 dotatate × Clear all
NCT03001349 2021-02-15

68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
4 enrolled
CNSEndocrineNET

von Hippel-Lindau Disease, Meningioma, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT02177773 2019-11-12

DOTA-TOC

University of California, San Francisco

Phase 1/2 Terminated
300 enrolled 5 charts
CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡